期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
The IL13α 2R paves the way for anti-glioma nanotherapy
1
作者 Ilya V.Ulasov Anton Borovjagin +4 位作者 Anastasia Laevskaya Margarita Kamynina Peter Timashev laura cerchia Elena A.Rozhkova 《Genes & Diseases》 SCIE CSCD 2023年第1期89-100,共12页
Glioblastoma(GBM)is one of the most aggressive(grade IV)gliomas characterized by a high rate of recurrence,resistance to therapy and a grim survival prognosis.The long-awaited improvement in GBM patients'survival ... Glioblastoma(GBM)is one of the most aggressive(grade IV)gliomas characterized by a high rate of recurrence,resistance to therapy and a grim survival prognosis.The long-awaited improvement in GBM patients'survival rates essentially depends on advances in the development of new therapeutic approaches.Recent preclinical studies show that nanoscale materials could greatly contribute to the improvement of diagnosis and management of brain cancers.In the current review,we will discuss how specific features of glioma pathobiology can be employed for designing efficient targeting approaches.Moreover,we willsummarize the main evidence for the potential of the IL-13R alpha 2 receptor(IL13α2R)targeting in GBM early diagnosis and experimental therapy. 展开更多
关键词 Braintumor Experimental therapy GBM IL-13Ra.2 Nanoparticles RECEPTOR Viral vectors
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部